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ABSTRACT
Introduction HIV programmes in sub- Saharan Africa 
are well funded but programmes for diabetes and 
hypertension are weak with only a small proportion of 
patients in regular care. Healthcare provision is organised 
from stand- alone clinics. In this cluster randomised trial, 
we are evaluating a concept of integrated care for people 
with HIV infection, diabetes or hypertension from a single 
point of care.
Methods and analysis 32 primary care health facilities in 
Dar es Salaam and Kampala regions were randomised to 
either integrated or standard vertical care. In the integrated 
care arm, services are organised from a single clinic where 
patients with either HIV infection, diabetes or hypertension 
are managed by the same clinical and counselling teams. 
They use the same pharmacy and laboratory and have 
the same style of patient records. Standard care involves 
separate pathways, that is, separate clinics, waiting and 
counselling areas, a separate pharmacy and separate 
medical records. The trial has two primary endpoints: 
retention in care of people with hypertension or diabetes 
and plasma viral load suppression. Recruitment is 
expected to take 6 months and follow- up is for 12 months. 
With 100 participants enrolled in each facility with diabetes 
or hypertension, the trial will provide 90% power to detect 
an absolute difference in retention of 15% between the 
study arms (at the 5% two- sided significance level). If 100 
participants with HIV infection are also enrolled in each 
facility, we will have 90% power to show non- inferiority 
in virological suppression to a delta=10% margin (ie, that 
the upper limit of the one- sided 95% CI of the difference 
between the two arms will not exceed 10%). To allow 
for lost to follow- up, the trial will enrol over 220 persons 
per facility. This is the only trial of its kind evaluating the 
concept of a single integrated clinic for chronic conditions 
in Africa.
Ethics and dissemination The protocol has been 
approved by ethics committee of The AIDS Support 
Organisation, National Institute of Medical Research and 
the Liverpool School of Tropical Medicine. Dissemination 
of findings will be done through journal publications and 
meetings involving study participants, healthcare providers 
and other stakeholders.
Trial registration number ISRCTN43896688.
INTRODUCTION
In sub- Saharan Africa, over 2 million deaths 
a year are attributed to hypertension and 
diabetes annually and this number is rising 
rapidly.1–3 Health service provision for these 
conditions and for HIV, which also requires 
chronic lifelong care, is organised separately 
from vertical stand- alone clinics across sub- 
Saharan Africa. This duplicates resources 
and is particularly difficult to access for 
Strengths and limitations of this study
 ► This is the largest trial of its kind with replication in 
over 30 health facilities and 2 countries.
 ► It was designed, implemented and is being moni-
tored in partnership with patient representatives, 
healthcare providers, policy- makers and other 
stakeholders.
 ► The trial is measuring objective markers of effec-
tiveness and is multidisciplinary.
 ► The trial has a relatively short follow- up of 12 
months and cannot estimate effect against mortality 
or other longer- term outcomes.
 ► The trial cannot be blinded—both healthcare pro-
viders and patients know the intervention being de-
livered at each health facility.
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the increasing number of people who have multiple 
conditions.4
There is little or no evidence that integration of primary 
care health services improves the health status of people 
in low- income or middle- income countries.5 6 Studies from 
sub- Saharan Africa evaluating complete integration—that 
is, a single clinic that can manage multiple chronic condi-
tions—for people living with any one or more chronic 
conditions are particularly scarce.7 We found one study 
from a Médecins Sans Frontières—supported health 
facility serving an informal settlement in Nairobi, Kenya. 
Patients with either HIV infection or non- communicable 
conditions (mostly hypertension) were seen together for 
basic monitoring and provision of drugs. However, the 
study size was just 1432 patients, it was retrospective and 
done at a single site.8 Limited evidence is also available 
from South Africa,9 10 but the health system here is much 
stronger and findings difficult to generalise to other parts 
of sub- Saharan Africa.
Given the limited evidence, we first conducted a large 
preliminary study to evaluate the acceptability and feasibility 
of integration of services for HIV, diabetes and hypertension 
in Tanzania and Uganda. We enrolled 2273 participants in a 
cohort study to receive integrated care from 10 health facili-
ties and followed the cohort for between 6 and 12 months. 
Retention was high and analysis suggested that the inte-
grated model could be highly cost- effective.11 However, the 
study did not have a comparative group. Here, we present 
the plans for a large pragmatic cluster- randomised trial that 
follows the initial study and is designed to inform policy.







Selection of health facilities 
Inclusion criteria: 
-Provides dedicated care for diabetes and HIV-infection 
in separate clinics 
Exclusion criteria: 
-Provides specialist referral care 
-Does not provide diabetes services 
 
Selected health facilities invited to 
participate in the study 
 
Final analysis of cluster randomised trial, using co-primary endpoints ascertained over a 12-month follow-up 
(1) Retention in care for patients on diabetes and hypertension management (powered to test superiority) 
(2) Plasma viral load suppression among persons HIV-infected (powered to test non-inferiority).  
Secondary endpoints include health economics indicators and process measures.  
Baseline, 6-months and at 12 months  
Integrated care (no. of health facilities = 16) 
Approximately 220 persons in each facility, and 





(no. of health facilities = 32) 
 
Standard care (no. of health facilities = 16) 
Approximately 220 persons in each facility, and 




Baseline, 6-months and at 12 months  
Data 
Figure 1 Trial schema. The INTE- AFRICA trial: a pragmatic parallel arm cluster randomised trial.
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METHODS
The INTE- AFRICA trial is a pragmatic parallel arm 
cluster randomised- controlled trial, comparing inte-
grated health services for HIV infection diabetes and 
hypertension with a standard care approach (ie, stand- 
alone care) in Tanzania and in Uganda. Health facili-
ties have been randomised to either integrated care or 
current standard care. Enrolment began on 30 June 2020 
and finished in April 2021. Follow- up will continue for 12 
months. Figure 1 shows the trial schema. Procedures for 
enrolment and the management of participants are iden-
tical in the two arms. The research team sees the partici-
pants at baseline, 6 months and 12 months and each time 
they self- refer (eg, attend because they are sick) for data 
collection.
The integrated care arm comprises:
 ► A single clinic where patients with either HIV infec-
tion, diabetes or hypertension are managed. Patients 
can have one or more of these conditions.
 ► There is one area where patients register and wait.
 ► They are managed by the same clinicians, nurses, 
counsellors and other staff.
 ► There is one pharmacy where the dispensing of medi-
cines is integrated.
 ► Patient records are the same for all patients.
 ► Laboratory samples are managed and tested in the 
same laboratory service where possible.
 ► Patients usually attend health facilities 3- monthly for 
routine appointments.
The standard vertical care provided in Tanzania and 
Uganda is the control arm and comprises:
 ► Vertical care in separate clinics for HIV infection, 
diabetes and hypertension, (ie, standard current 
practice).
 ► HIV services have separate waiting areas and separate 
consultation rooms, a separate dedicated pharmacy, 
separate medical records and laboratory samples 
are managed separately from those for diabetes and 
hypertension services.
 ► Patients with HIV usually attend for routine appoint-
ments 3- monthly but those with diabetes or hyperten-
sion attend their clinics monthly.
 ► Diabetes and hypertension services continue as 
they are. Patients with these conditions are usually 
managed in separate clinics and they use the general 
hospital pharmacy. These patients will usually attend 
health facilities monthly for routine appointments.
Thousands of patients are receiving care for HIV infec-
tion, diabetes and hypertension at each health facility but 
for the sample size requirements, we only need to enrol a 
subset of participants at each facility. Therefore, in those 
facilities randomised to integration, stand- alone ‘inte-
grated clinics’ have been set up. In some facilities, these 
run on a day when the separate standalone HIV, diabetes 
and hypertension clinics are not operating. In others, 
it is run in separate rooms away from the main vertical 
standalone clinics. In the standard care, participants are 
enrolled into the research study and continue to receive 
standard care.
We have attempted to bring clinical staff to a common 
level of understanding of the management of HIV infec-
tion, diabetes and hypertension in both the arms of the 
trial. Thus, government clinical and counselling staff have 
had classroom training on the management of HIV infec-
tion, diabetes and hypertension for 1–2 days. Both health-
care and all research staff have also received training on 
the protocol, also for 1 day.
Thereafter, staff received on- the- job training for a 
period of 1 month. Within the integrated care clinics, 
staff specialised in one condition supported staff new to 
managing the other two conditions. For example, the 
doctors who have traditionally managed patients with 
HIV infection periodically observe staff from diabetes 
and hypertension clinics treating HIV- infected patients. 
They provide constructive feedback and support.
Staff in the vertical standalone clinics also receive 
on- the- job training. Those managing the single condi-
tions are observed at least once every week for 4 weeks. 
They receive constructive feedback and support.
Patient and public involvement
How was the development of the research question and outcome 
measures informed by patients’ priorities, experience and 
preferences?
We conducted a large pilot study. Integrated care clinics 
for patients living with HIV infection, diabetes or hyper-
tension were set up in 10 health facilities in Tanzania and 
Uganda. Over 2000 patients with one or more of these 
chronic conditions were followed up for 6–12 months. 
Acceptance was high and retention in care at the study 
end exceeded 80%. Integrated care was particularly 
welcomed by patients who had more than one condition 
Table 1 Total number of facilities needed in both arms 
to demonstrate absolute differences of between 10% and 
20% for different values of variation between health facilities 
(intraclass coefficient of variation) and of numbers of 







Proportion retained in care in 
the integrated care arm
70% 75% 80%
0.05 50 74 32 18
0.06 50 84 36 20
0.07 50 94 40 22
0.05 100 64 28 16
0.06 100 74 32 18
0.07 100 86 36 20
0.05 200 60 26 14
0.06 200 70 30 16
0.07 200 80 34 20
The calculations assume 90% power and a two- sided significance 
level of 5%.
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and who would otherwise visit the health facility multiple 
times.
Before the pilot study started, we set up steering commit-
tees in both Tanzania and Uganda, which comprised 
researchers, policy- makers and had patient representa-
tives. We held investigator meetings involving all of the 
partners. These included a patient representative and 
at the last meeting, held in December 2019 in Uganda 
(prior to the start of this trial), one of the patient repre-
sentatives gave a talk on why integrated management was 
important to him and other patients.
How did you involve patients in the design of this study?
Patient representatives attended our planning meetings 
and contributed to the design of the study and other 
aspects of the research, such as its implementation.
Are patients involved in the recruitment to and conduct of the 
study?
Patient representatives remain on the steering commit-
tees and are invited to the large investigator meetings. 
The steering committees meet every 3–6 months. At these 
meetings, patient representatives provide input into the 
recruitment and conduct of the study.
How will the results be disseminated to study participants?
This will be done through information leaflets, written 
for study participants. We will distribute these to all study 
participants. We will also present the findings to the 
steering committees, which are attended by patient repre-
sentatives, and publish the findings in a journal.
For randomised controlled trials, was the burden of the intervention 
assessed by patients themselves?
The patients were fully informed about the intervention. 
The intervention was designed to reduce the burden of 
visits for patients.
Governance and oversight
As mentioned above, each partner country has a steering 
committee. There is also a single international steering 
committee, which is chaired by and has majority partici-
pation of independent researchers, and an independent 
data and safety monitoring committee. The composition 
and charter of the independent data and safety moni-
toring committee is available on request.
The trial Sponsor is the Liverpool School of Tropical 
Medicine ( lstmgov@ lstmed. ac. uk).
Study design and setting
INTE- AFRICA comprises 32 health facilities that have 
been randomised in the 2 countries—16 to integrated 
care and 16 to the standard care (control arm). Seven-
teen facilities are in Uganda and 15 in Tanzania. Health 
policies in both countries support integrated manage-
ment for chronic conditions but clinical practice involves 
vertical healthcare delivery for HIV, diabetes and hyper-
tension, with clinics for these conditions typically run on 
different days of the week in most health facilities.12 As 
in most of sub- Saharan Africa, shortages in medicines for 
diabetes and hypertension are common.13–15 HIV services 
are organised in separate areas of the health facilities, with 
separate clinical and counselling staff, separate medicines 
procurement and separate medical records.16
The trial is being done in close to normal health service 
conditions, with government healthcare staff managing 
patients.17 Thus, healthcare provision, including setting 
up of the integrated care clinics, has been done by health 
services, with limited support from the research team. The 
research team organised basic training in the manage-
ment of patients with chronic conditions, as mentioned 
above, and supported health facilities to strengthen 
the provision of medicines supply for hypertension and 
diabetes.18 In Uganda, in a few health facilities in the 
region, groups of participants had formed ‘clubs’ whereby 
each patient contributes money into a single fund and the 
Club uses it to purchase drugs when government supplies 
are limited. The research team supported the health 
facility managers to kick- start these Clubs in each facility 
participating in the trial for the purchase of medicines for 
diabetes and hypertension. The health facility managers 
gathered patients together to discuss procedures, the 
setting up of a common bank account, and agreeing a 
drug procurement and dispensing system. Each patient 
contributed about £5 per month. The bulk purchasing 
led to a 50%–60% reduction in drug costs compared with 
pharmacy prices. The drugs were delivered to the facility 
pharmacy, which distributed them to participants. This 
was done by the pharmacist and overseen by one of the 
patient volunteers. To support this effort, the research 
team provided buffer drug supplies for 2 months when 
a facility ran short to enable the patients’ central fund to 
grow and after this period, the club was self- sustaining.
In Tanzania, some patients are on insurance schemes 
and so had a reliable medicines supply. Others were 
expected to pay for their medicines if they could afford 
this. The health facilities have an established protocol for 
evaluating patients who have no insurance and are not 
able to pay. The project provided a buffer to the facili-
ties for the few patients that are not able to purchase the 
drugs.
Research data collection is minimal and done mostly 
by trained researchers while patients wait for consulta-
tions. For our coprimary endpoint of plasma viral load 
suppression, samples are taken by healthcare staff and 
tested in government laboratories. Where needed, the 
research programme pays for the tests and the data are 
used by both the research team and the healthcare teams 
for patient management.
INTE- AFRICA is being conducted in medium- large 
sized health facilities that focus on offering ambulatory 
care. All of the facilities are run by physicians or medical 
officers, supported by part- qualified physicians (clin-
ical officers or assistant medical officers). The facilities 
are located in largely urban settings in Dar es Salaam 
in Tanzania and Kampala region in Uganda. They were 
selected according to the following criteria:
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Inclusion criteria
 ► Provides dedicated care for diabetes and HIV infec-
tion in separate clinics.
 ► Has a minimum of n=100 patients in care with 
diabetes.
Exclusion criteria
 ► Provide specialist referral care.
 ► Does not provide diabetes services.
We chose to enrol facilities that have dedicated separate 
clinics for HIV infection and diabetes. We have not spec-
ified hypertension in our inclusion criteria. In the health 
facilities where we are working, hypertension clinics are 
sometimes standalone and sometimes integrated with 
diabetes clinics, depending on the volume of patients. 
Since these health facilities currently provide care sepa-
rately for HIV infection and diabetes/hypertension, inte-
gration will involve the greatest change for the health 
facility and therefore the greatest advance in knowledge. 
Diabetes care is fragmented and screening to identify 
people with diabetes is limited. We had a minimum of 100 
people with diabetes as a requirement since some clinics 
manage few patients with diabetes.
We are not intervening in large referral hospitals that 
offer specialised care. They act as referral centres. We are 
also not enrolling at smaller health facilities that do not 
offer diabetes services as such facilities could not act as 
effective control clinics for vertical care.
Government health facilities fulfilling these criteria are 
large health centres (health centre IVs and a few health 
centre IIIs) in Uganda. In Tanzania, the comparable 
centres are the smaller district and municipal hospitals, 
and the larger health centres.
In both Tanzania and Uganda, the not- for- profit non- 
governmental organisations (NGOs) are responsible 
for a substantial amount of healthcare delivery, which is 
organised in accordance with national guidelines. They 
are also major players in training and strengthening 
healthcare provision in government health facilities. We 
are recruiting a small number of NGO- run health facil-
ities that are similar to the government health facilities 
providing dedicated primary healthcare.
We chose the regions, based on ease of access for the 
research team. We then visited the large facilities that 
fulfilled the criteria above. We omitted a small number 
that were inaccessible.
In the selection of study participants, we kept the 
criteria minimal so as to maximise generalisability of 
findings.
Inclusion criteria
 ► Adult, 18 years or older.
 ► Confirmed HIV infection, diabetes or hypertension.
 ► Living within the catchment population of the health 
facility.
 ► Likely to remain in the catchment population for 6 
months.
 ► Willing to provide written informed consent.
Exclusion criteria
 ► Sick, requiring immediate hospital care.
We know that at each of the study health facilities, the 
numbers of patients receiving diabetes care or those with 
multiple conditions are limited and so patients with these 
conditions are being enrolled consecutively.
The health facilities have a high volume of patients 
with HIV infection and with hypertension. Some health 
facilities do not offer appointments and so there is no 
way of knowing who will present the next day. In larger 
health facilities, appointments are given out in 3–4 blocks 
during the day so as to spread the patient load.
Selection of patients using simple random sampling 
minimises bias but is difficult to achieve. Therefore, we 
are conducting systematic sampling to enrol patients with 
HIV infection or hypertension—that is taking every 5th 
or 10th patient consecutively in order of their attendance 
at the health facility, depending on the patient load. If the 
study team are late arriving at the facility, or if a patient 
refuses to join the study, then they maintain the system-
atic sequence and start at the next sequence number (ie, 
offer enrolment to the next 5th or next 10th patient).
In the HIV or hypertension clinics, patients’ details 
are entered onto a clinic register when they arrive and 
research staff use the register to determine the first 
patient for enrolment, second patient and so on.
Sampled patients are then invited to participate in the 
trial following written informed consent.
RANDOMISATION
The study is cluster randomised since the intervention is 
delivered at a clinic level.
There is considerable variation in infrastructure 
and service provision between health facilities. There-
fore, to ensure balance between the intervention and 
control arms, we stratified the randomisation. The strata 
comprised:
1. District hospitals or large health centres.
2. Health centres or large dispensaries.
3. Not- for- profit health facilities.
Within each stratum, we randomised facilities in a 1:1 
ratio to either integrated care or standard care using a 
permuted block randomisation method generated by 
SAS PROC PLAN (V 9.4).
We considered changing the mode of care entirely for 
all patients at each clinic to either integrated or vertical 
care, depending on the randomisation. This would have 
replicated real life healthcare delivery. However, it would 
have represented a major change for the health services, 
without the evidence to support such a move. It would 
also have meant that those people who were currently 
receiving vertical care and did not wish to change, would 
not have had the choice to continue. Therefore, although 
randomised by clinic, we are enrolling only a small 
proportion of the very many patients attending health 
services at the clinic. In the clinics randomised to provide 
integrated care, they are the sole point of integration in 
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that facility for HIV infection, diabetes and hypertension 
as integrated services are not provided anywhere else in 
either country.
PRIMARY ENDPOINTS
The study has two coprimary endpoints, which will be 
ascertained over a 12- month follow- up:
 ► Retention in care for patients on diabetes and hyper-
tension management. This is measured as the propor-
tion of people alive and in care at 12 months of 
follow- up.
 ► Plasma viral load suppression among persons HIV 
infected. This is defined as plasma viral load less than 
1000 copies per mL.
We will define a participant as being retained in care 
if he/she has attended clinic for their routine 6- month 
assessment or anytime after that and in the subsequent 
6 months (ie, up to month 12), that he/she has not been 
declared lost to follow- up, has not withdrawn and has not 
died.
Participants who have transferred away for their care 
will be contacted by phone. In many cases, this will be 
because of referral for specialist care. If they are still in 
care in the places that they transferred out to, then they 
will be assumed to be retained for the purposes of the 
primary analysis.
Viral suppression will be defined as a viral load of  <1000 
copies per mL (or reported as undetectable viral load). 
Any viral load measurements taken at or after 6 months 
after enrolment in the trial will be used in this endpoint 
analysis.
Rationale
Retention in care is fundamental to disease control and 
has been very low for people with diabetes or hyperten-
sion in African settings, even where healthcare and medi-
cines are provided for free. It is also a common indicator 
to both conditions.
We considered blood pressure and glycaemia control as 
primary endpoints but decided on retention as that is the 
immediate aim of our intervention. Once African health 
services can achieve good retention, the next stage of the 
research will be to assess impact on clinical indicators. 
At present, there are few reliable background data from 
Africa on blood pressure and glycaemia control achieved 
by populations able to access treatments. However, in 
high- income countries, only about one in four persons 
with known hypertension and one in two persons with 
known diabetes achieve adequate blood pressure and 
glycaemia control, respectively, and control is poorer in 
low- resource settings.19–22
We also considered a disease- based composite outcome 
such as either a stroke, myocardial infarction, or all cause- 
mortality, but this would need many years of follow- up. 
Also, given the poor retention in care, measuring disease 
incidence is fraught with bias. For these reasons, we chose 
retention as one of the primary endpoints.
The trial will also test whether there is an adverse effect 
of integrated services on HIV outcomes. In other words, 
does integration lead to poorer HIV viral suppression as 
compared with standard vertical care? To answer this ques-
tion, HIV viral load was selected as a coprimary endpoint.
Secondary endpoints will include control of blood pres-
sure and glycaemia, cost of illness and healthcare, inci-
dence of clinical events including hospital admissions 
and deaths and plasma viral load  >100 copies per mL. 
Definitions of the control of blood pressure will include 
achieving a blood pressure  <140/90 mm Hg and of 
diabetes as achieving fasting blood glucose  <7 mmol/L. 
The indicators will also be analysed on a continuum.
Although the study has two coprimary outcomes, they 
are being measured in different populations, one among 
people with hypertension or diabetes and the other in 
people with HIV infection. The plasma viral load is also 
a safety outcome in that we wish test whether integration 
could do harm to outcomes of people with HIV infec-
tion. Therefore, we will not adjust the final analyses for 
multiplicity.
Sample size considerations
Retention in care endpoint
We assumed that with the training and improved proce-
dures, retention in care for persons with diabetes and 
hypertension would improve under current standard 
care—probably to a figure around 60%–70%. As a 
comparison, for HIV infection, this figure was around 
70%–80% prior to about 2006 and is generally around 
90% today.23
We hypothesised that in the intervention arm, inte-
gration would lead to further improved retention rates 
compared with the standard vertical care for diabetes and 
hypertension. Thus, this endpoint was powered on an 
assumption of superiority.
The sample size calculation must take clustering at 
health facility into account (ie, the variation between 
health facilities as well as variation between patients). 
We have done this for different values of the intraclass 
correlation coefficient. This is a measure of the variation 
between health facilities, which we can minimise between 
arms by stratification. In many trials, the intraclass correla-
tion coefficient is assumed to be 0.05 but we were conser-
vative in accepting a higher level of variation of 0.06.24 25
The calculations show that for hypertension and 
diabetes, if the retention in the standard vertical care arm 
is 60% at 12 months, then 32 facilities (16 randomised 
to integration and 16 to standard vertical care), with 100 
patients studied in each facility, will provide 90% power 
to detect an absolute difference of 15% between the two 
study arms (ie, a retention of 60% vs 75%, respectively, in 
the standard care and intervention arms) (table 1). If the 
variation between health facilities turns out to be higher 
(ie, intraclass coefficient is 0.07, power will still exceed 
80%). If the retention rate in the control arm is 70%, 
then power to detect differences will be even higher.
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We will enrol 110 patients in each of the 32 facilities to 
allow for a 10% refusal rate. This refusal rate is conser-
vative as in previous large studies in these settings, our 
refusal rate has been close to zero.26 The group of 110 
patients in each facility will be a mix of persons with 
either diabetes or hypertension or both conditions. The 
total number of patients within this randomised evalua-
tion will be 3520.
HIV plasma viral load endpoint
The sample size for the HIV component is calculated 
to show non- inferiority between the integration and 
the standard vertical care arms. We will enrol the same 
number of persons with HIV infection (3520 comprising 
110 patients in each of 32 facilities) as the number with 
hypertension or diabetes in the cluster randomised trial.
The numbers of HIV- infected people with known 
diabetes, hypertension or both is likely to be small as 
testing is limited across Africa. We will enrol all patients 
with known multimorbidity to add to the 3520 HIV- 
infected persons and 3520 with diabetes or hypertension.
In terms of virological suppression, if we assume that 
this is 85% at 12 months in the standard care arm, we will 
have 90% power to show non- inferiority between the two 
arms to a delta=10% margin (ie, that the upper limit of 
the one- sided 95% CI of the difference between the stan-
dard care and intervention arms will not exceed 10%). 
This also assumes an intraclass coefficient of variation of 
0.06 and one- sided 95% CI.
Health economics endpoints
A substudy on costs is nested in the trial. Its aim is to 
provide evidence on the costs associated with accessing 
care for study participants and the costs of delivering care 
from the health providers perspective.
The economic evaluation will be based on the clin-
ical and operational outcome parameters to define the 
economic effectiveness outcomes. The primary outcomes 
will be the incremental cost per additional person 
retained in the programme and the incremental cost 
per additional person virologically suppressed. Other 
outcomes will be the healthcare cost per patient category 
per year in integrated care and standard care, the average 
healthcare costs per additional patient treated and the 
change in the average healthcare costs/societal cost per 
additional patient with a controlled condition.
Given that costs and benefits of integrated care services 
may extend beyond the follow- up period and that these 
chronic conditions have lifelong consequences, we will 
construct an individual- based microsimulation model 
to estimate the long- term and lifelong cost- effectiveness 
of different methods of care for patients with different 
conditions and explore the cost- effectiveness of future 
scale up of these healthcare approaches.
Statistical analysis
The primary indicators will be compared between the 
intervention arm and standard care, while controlling 
for possible confounders, defined a priori. General esti-
mating equation models will be used for the analysis to 
take account of clustering of data within health facilities.
The primary measure of effectiveness for the primary 
outcomes will be absolute risk differences and risk ratios. 
Time to event analysis—that is, time to loss from care—
will also be conducted. We will not adjust for multiple 
comparisons. Although we have two coprimary endpoints, 
they are in different populations.
An intention- to- treat analysis strategy will be used for 
the primary analysis. Every effort will be made to minimise 
missing outcome data at each visit. Sensitivity analyses will 
be conducted to assess the robustness of the missing data 
assumption made in the primary analysis. Detailed statis-
tical analyses will be described in the statistical analysis 
plan.
Process evaluation
Concurrent process evaluation is being done alongside 
the implementation of INTE- AFRICA to understand the 
context, description of the intervention and its causal 
assumptions, implementation, mechanisms of impact 
and outcomes and document stakeholders experiences, 
attitudes and practices during implementation, and 
to understand the impact of structural and contextual 
factors (macro/meso/micro) on implementation.27 This 
is described elsewhere.4
Data management
The study is run in accordance with good clinical prac-
tice. This involves regular monitoring of procedures and 
checking of data collected. A custom electronic database 
has been designed for the trial. Staff received training 
on the electronic database as well as on how to report 
issues and make suggestions. Trial data are collected 
and validated electronically in real- time with built in 
data type and logic checks with the patient at the point 
of care. The real- time validation logic is custom to the 
protocol and references new and existing patient data 
for immediate feedback to the user. Data modifications 
are tracked in a comprehensive electronic audit trail so 
as to not obscure changes. Changes to the source code of 
the electronic database are tracked and versioned. The 
current software version is stamped on each record as it 
is modified.
Data may be viewed, created, modified, deleted or 
exported by delegated persons according to the access 
roles associated with their personal accounts. The 
sponsor and other relevant parties may be given access 
to data separately with suitable notice. Security of data is 
ensured using authentication and encryption to render 
subject identity and personal health information unus-
able, unreadable and indecipherable to unauthorised 
individuals. The application and database layers use a 
combination of hashing and field- level encryption for 
sensitive and personal data. Study data are not stored on 
devices in the field.
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Ethics and dissemination
The protocol has been approved by ethics committee 
of The AIDS Support Organisation, Uganda (reference 
number TASOREC/090/19- UG- REC- 009), National Insti-
tute of Medical Research, Tanzania (reference number 
NIMR/HQ/R.8a/Vol. IX/3394, 23 March 2020) and the 
Liverpool School of Tropical Medicine, UK (reference 
number 19- 100, 2 July 2020).
The findings of the study will be shared with policy- 
makers and senior programme managers, with civil 
societies (including the East African NCD (Non Commu-
nicable Disease) Alliance, the Tanzania Diabetes Asso-
ciation and others), with patient groups and with the 
participants. The findings will also be published in peer- 
reviewed journals.
DISCUSSION
In this trial, we are testing the concept of a single chronic 
care clinic where people living with any one or more of 
the target conditions—HIV infection, diabetes or hyper-
tension—may come for health services and care. Very 
few settings in Africa have even attempted screening of 
people with HIV infection for chronic conditions, despite 
their high prevalence. To our knowledge, there have 
been no attempts of a fully integrated approach to these 
chronic conditions as being tested in this trial.
This approach is controversial on a number of fronts. 
The HIV programmes are well funded and have achieved 
high levels of coverage of antiretroviral therapy across 
Africa, and we are asking them to merge with much 
weaker programmes. Patients have traditionally been 
managed in standalone specialist clinics and we are now 
asking them to move to management by generalist clin-
ical staff, which will seem inferior to many specialists. 
Finally, patients with HIV infection have always been 
segregated from others, and we are now asking everyone 
to sit together, which will be uncomfortable to some due 
to the stigma associated with HIV infection.
Furthermore, the research programme cannot compen-
sate government clinical staff for the added time that 
the research will take, pay for medicines or compensate 
patients for their time, unlike the situation in many clin-
ical trials. For our findings to be relevant to policy- makers 
and other stakeholders, healthcare must be provided in 
close to normal health service conditions.
Central to the success of such research is the devel-
opment of partnerships with policy- makers, healthcare 
managers and providers, patient groups and community 
representatives. Each of these stakeholders, in particular 
the policy- makers, are consulted at regular intervals and 
to date, they have given considerable time in setting the 
research strategy and the design and implementation of 
the research studies. Over time we created formal struc-
tures to ensure their voices were heard. Each country has 
a steering committee that includes representatives of the 
stakeholders, and which meets at least 3- monthly. We also 
have an international steering committee, which includes 
representation from the different partners and is domi-
nated by independent researchers.
The study also involves researchers from multiple 
different disciplines, including clinical trialists and stat-
isticians, social scientists and health economists, clinical 
researchers and programme managers and from both 
African and European institutions. Crucial to the success 
of the research programme to date has been that we 
operate on an ethos of equality and openness. This means 
that meetings are an inclusive opportunity and support 
where needed is given to people to contribute. We have 
also invested in training in communications and uncon-
scious bias.
We have focused on just three conditions, and of the 
non- communicable conditions, we chose diabetes and 
hypertension as these are responsible for a very high 
disease burden and are probably more modifiable by inter-
vention than many other chronic conditions. However, 
we see the test of these three conditions in integration as 
a test of proof of concept so that if integration is shown to 
be effective, expansion to include other conditions could 
be considered.
Although the trial is large, we are testing integration in 
a small proportion of patients attending health facilities. 
The evidence was simply lacking to change the health-
care model at each clinic. Thus, further research will be 
needed to estimate the effects of transforming entire 
clinics to integration.
We did consider other study designs to answer our ques-
tion. For example, it would have been possible to recruit 
patients in integrated and in vertical care from the same 
health facilities as the clinics often run on different days. 
This could have reduced costs; but risked greater contam-
ination between the intervention and control arms and 
risked confusion among busy clinical staff and facility 
managers.
A challenge of such cluster randomised trials is that 
participants and clinicians cannot be blinded, and 
further, that people may have their biases of which inter-
vention should work. Thus, we have restricted evaluation 
to largely biomedical objective endpoints. We also train 
staff regularly, reminding them of the critical role of equi-
poise in trials.
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